Firstsource is leveraging AI and tech for growth, launching various initiatives. It also secured several large deals, showcasing its ability to land transformative partnerships and drive growth. Dolat Capital believes a strong deal pipeline would provide continuity to this. There is optimism for Healthcare while BFS is expected to be steady which would be key in driving further growth momentum.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Firstsource Solutions Ltd. reported rev. at $250 million (our estimate: $252 million), up 2.1% QoQ in constant currency terms (organic growth muted). Operating profit margin came in at 11.2%, up 11 bps QoQ (our estimate: 11.3%).
For FY26, the management guided CC revenue growth of 12%-15% (implies organic band of 7-10%) and OPM guidance of 11.25%-12%. The company also aims to improve margins by 50-75 bps each year over next three-four years to align its OPM with industry peers.
Given a strong pipeline and management’s confidence in achieving a good conversion rate supported by positive commentary and outlook on major revenue verticals, we have maintained our FY26E/FY27E EPS estimates.
The present valuations capture most positives and upside being limited we maintain our ‘Reduce’ rating with target price of Rs 370 (valuing at 28x FY27E EPS).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Voltas Eyes Q3 Recovery Amid Short-Term Headwinds; Anand Rathi Retains 'Buy'


Bharat Forge Q1 Review — Yes Securities Downgrades The Stock To 'Add' To Factor In Prevailing Uncertainty


Triveni Turbine Q1 Review — Centrum Broking Maintains 'Buy' With A Revised Target Price Of Rs 650


Sun Pharma Q1 Review — Dolat Capital Maintains 'Reduce', Sees Current Valuations To Limit Upside
